EUVIMEDEUVIMED entdecken
Multizentrische Studie

Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy

Elena Herranz-Bayo, Luis Enrique Chara-Velarde, Javier Cassinello-Espinosa, Vicente Gimeno-Ballester, Ángel Artal-Cortés, Alba Moratiel-Pellitero, Arancha Alcácera-López, Fátima Navarro-Expósito, Blanca Riesco-Montes, Manuel Clemente-Andujar

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03690-3 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Elena Herranz-Bayo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Universitario Miguel Servet, P.º de Isabel La Católica, 1-3, 50009, Zaragoza, Spain. eherranz@salud.aragon.es. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Combined Chemotherapy Protocols, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The lung immune prognostic index (LIPI) is a biomarker that combines the lactate dehydrogenase (LDH) value and the derived neutrophil/lymphocyte ratio (dNLR). Its prognostic ability has been reported in non-small cell lung cancer (NSCLC) with immunotherapy. In the context of extensive-stage small cell lung cancer (ES-SCLC) with chemoimmunotherapy, its role remains to be determined. METHODS: A retrospective, multicenter study of patients with ES-SCLC who received atezolizumab plus chemotherapy as first-line treatment was conducted. 101 patients were divided into three groups: LIPI good (n = 33), LIPI intermediate (n = 41), and LIPI poor (n = 27). The Kaplan-Meier method was used for analysis of overall survival (OS) and progression-free survival (PFS), using the log-rank test for comparisons. Univariate and multivariate Cox models were developed to assess the LIPI as an independent predictor of survival. RESULTS: The good LIPI group had a significantly longer median PFS than the intermediate and poor LIPI groups: 9.6 vs 5.4 vs 5.2 months, respectively (p < 0.001). Significant differences in OS between good, intermediate, and poor LIPI were also observed, with median OS of 23.4 vs 9.8 vs 6.0 months, respectively (p < 0.001). Multivariate Cox regression analysis for PFS identified liver metastases and intermediate and poor LIPI as worse prognostic factors (p < 0.050). For OS, a worse prognosis was confirmed in both the intermediate LIPI group (HR: 2.18, 95% CI: 1.07-4.41, p = 0.031) and the poor LIPI group (HR: 5.40, 95% CI: 2.64-11.07, p < 0.001). CONCLUSIONS: In patients with ES-SCLC treated with chemoimmunotherapy, an intermediate and poor pretreatment LIPI score was associated with worse PFS and OS prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSmall Cell Lung CarcinomaAntineoplastic Combined Chemotherapy ProtocolsImmunotherapyHumansMaleFemaleRetrospective StudiesAgedMiddle AgedPrognosisAntibodies, Monoclonal, HumanizedNeutrophilsL-Lactate DehydrogenaseAged, 80 and overProgression-Free SurvivalAdultLymphocytesBiomarkers, TumorSurvival Rate

Stichwörter der Autor:innen

ImmunotherapyLung immune prognostic indexPrognostic factorSmall cell lung cancer

Substanzen

atezolizumabAntibodies, Monoclonal, HumanizedL-Lactate DehydrogenaseBiomarkers, Tumor

Autor:innen und Institutionen

  • Hospital Universitario Miguel Servet, P.º de Isabel La Católica, 1-3, 50009, Zaragoza, Spain. eherranz@salud.aragon.es.
  • Hospital Universitario de Guadalajara, C. Donante de Sangre, S/N, 19002, Guadalajara, Spain.
  • Hospital Universitario Miguel Servet, P.º de Isabel La Católica, 1-3, 50009, Zaragoza, Spain.
  • Hospital Clínico Universitario Lozano Blesa, C. de San Juan Bosco, 15, 50009, Zaragoza, Spain.
  • Príncipe de, Hospital Universitario Príncipe de Asturias, Av. Principal de La Universidad, S/N, 28805, Alcalá de Henares, Madrid, Spain.
  • Complejo Hospitalario Universitario de Albacete, C. Hermanos Falco, 37, 02006, Albacete, Spain.

Zitieren

APA

Herranz-Bayo, E., Chara-Velarde, L. E., Cassinello-Espinosa, J., Gimeno-Ballester, V., Artal-Cortés, Á., Moratiel-Pellitero, A., Alcácera-López, A., Navarro-Expósito, F., Riesco-Montes, B., & Clemente-Andujar, M. (2024). Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03690-3

Vancouver

Herranz-Bayo E, Chara-Velarde LE, Cassinello-Espinosa J, Gimeno-Ballester V, Artal-Cortés Á, Moratiel-Pellitero A, et al. Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03690-3

BibTeX
@article{HerranzBayo2024,
  author = {Herranz-Bayo, Elena and Chara-Velarde, Luis Enrique and Cassinello-Espinosa, Javier and Gimeno-Ballester, Vicente and Artal-Cortés, Ángel and Moratiel-Pellitero, Alba and Alcácera-López, Arancha and Navarro-Expósito, Fátima and Riesco-Montes, Blanca and Clemente-Andujar, Manuel},
  title = {Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03690-3}
}
Kostenlos starten →